| Cardiovascular Risk Management |
1 |
1 |
| Lipids Management |
0 |
0.95 |
| Statins |
0 |
0.99 |
| Clinical Guidelines |
0 |
0.98 |
| Hypertension |
0 |
0.08 |
| Myocardial Infarction (MI) |
0 |
0.07 |
| Adverse Effects |
0 |
0.05 |
| Coronary Artery Calcification |
0 |
0.05 |
| Dyslipidemia |
0 |
0.05 |
| Heart |
0 |
0.05 |
| Hepatocellular Carcinoma |
0 |
0.05 |
| Infarction |
0 |
0.05 |
| LDL Cholesterol |
0 |
0.05 |
| Metabolic Syndrome |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |
| Aminotransferase |
0 |
0.04 |
| Cerebrovascular Accident |
0 |
0.04 |
| Familial Hypercholesterolemia |
0 |
0.04 |
| Accomodation |
0 |
0.03 |
| Artery |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Board Certification |
0 |
0.03 |
| Calcium |
0 |
0.03 |
| California |
0 |
0.03 |
| Cancer |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Comparative Effectiveness |
0 |
0.03 |
| Face |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Hand |
0 |
0.03 |
| Healthcare and Medical Technology |
0 |
0.03 |
| Hypercholesterolemia |
0 |
0.03 |
| Injury |
0 |
0.03 |
| Liver |
0 |
0.03 |
| Metabolism |
0 |
0.03 |
| Osteoarthritis |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Translational Research |
0 |
0.03 |
| Weakness |
0 |
0.03 |
| Wound Management |
0 |
0.03 |
| Young Adult |
0 |
0.03 |